Outcomes following percutaneous coronary revascularisation in acute coronary syndromes: a comparison of drug coated balloon versus drug eluting stent strategies in de novo large epicardial vessels
The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy, which was comparable to a DES only strategy.
Abstract
Drug coated balloons (DCB) in de novo large vessel disease and in acute coronary syndromes (ACS) remain under scrutiny with a paucity of data.
This study reports on outcomes of a DCB only strategy compared to a drug eluting stent (DES) only strategy in large epicardial coronary arteries in an ACS population.
Retrospective analysis of prospectively collected data on all ACS patients undergoing percutaneous coronary intervention (PCI) from January 2021 to June 2025. The primary outcome was medium to long term major adverse cardiovascular events (MACE).
There were 247 patients in the DCB arm with treated large epicardial vessels >3mm) and they were matched with 247 patients treated with DES. The median age was 64 (58-74) in the DCB group and 64 (57-73) in the DES group. No significant difference in MACE at median 21-month follow-up between the DCB and DES groups (10.1% vs 11.7%, p=0.94, all-cause mortality (5.3% vs 8.1%, p=0.44) or repeat revascularisation (4.9% vs 4.5%, p=0.49) in the DCB group compared to the DES group.
The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy.KM Graph of MACE after DCB and DES strategiesFor image description, please refer to the figure legend and surrounding text.
Drug-coated balloon (DCB) has emerged as potential alternative to drug-eluting stents (DES) in specific lesion subsets for de novo coronary lesions. However, evidence supporting DCB in severely calcified lesions remains limited. Quantitative flow ratio (QFR) is a noninvasive quantitative tool for evaluating post-...
Q. Qin, L. Chen, Ren-De Xu et al.· European Heart Journal· 0 citations
For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
Wen-Jie Wang, Hong-Fei Si, L. Li et al.· Reviews in cardiovascular me...· 0 citations
Drug-coated balloon (DCB)-based strategies are increasingly explored as an alternative or adjunct to drug-eluting stent (DES) implantation to reduce permanent metal burden. However, real-world data on the utilization and safety of DCB-based strategies in acute coronary syndrome (ACS) remain limited.
To eva...
F. Rode, A. Jordan, M. Radić et al.· European Heart Journal· 0 citations
AIM
Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...
Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al.· American Journal of Cardiolo...· 0 citations
BACKGROUND
Real-world data after percutaneous coronary intervention (PCI) using drug-coated balloons (DCBs) in acute coronary syndrome (ACS) are limited.
AIMS
We compared 1-year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non-ACS patients.
METHODS
The ALLIANCE is a prospective, multicenter...
Takashi Muramatsu, K. Tanabe, K. Kadota et al.· Catheterization and cardiova...· 0 citations
In patients with large coronary vessels and ACC/AHA type B2/C complex lesions, a DCB-only strategy demonstrated comparable but not superior 3-year outcomes compared with newer-generation DES, suggesting no procedural simplification advantage with DCB-only treatment.
R. Bando, K. Yamaguchi, Y. Kawabata et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.